RU2078815C1 - Strain of bacterium bifidobacterium breve used for preparing the bacterial curative-prophylaxis bifido-containing preparations - Google Patents
Strain of bacterium bifidobacterium breve used for preparing the bacterial curative-prophylaxis bifido-containing preparations Download PDFInfo
- Publication number
- RU2078815C1 RU2078815C1 RU9595100750A RU95100750A RU2078815C1 RU 2078815 C1 RU2078815 C1 RU 2078815C1 RU 9595100750 A RU9595100750 A RU 9595100750A RU 95100750 A RU95100750 A RU 95100750A RU 2078815 C1 RU2078815 C1 RU 2078815C1
- Authority
- RU
- Russia
- Prior art keywords
- strain
- bifidobacterium breve
- bacterial
- bifido
- prophylaxis
- Prior art date
Links
- 241000186012 Bifidobacterium breve Species 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000001580 bacterial effect Effects 0.000 title claims description 7
- 238000011321 prophylaxis Methods 0.000 title 1
- 244000005700 microbiome Species 0.000 claims abstract description 3
- 244000005706 microflora Species 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000000721 bacterilogical effect Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 abstract description 7
- 230000000813 microbial effect Effects 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 4
- 230000003042 antagnostic effect Effects 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 239000002028 Biomass Substances 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract description 2
- 230000003698 anagen phase Effects 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000186000 Bifidobacterium Species 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 108010081391 Ristocetin Proteins 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- -1 inuklin Chemical compound 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Изобретение относится к медицинской микробиологии и представляет собой штамм бифидобактерий, который может быть использован для приготовления бактерийных лечебно-профилактических бифидсодержащих препаратов. The invention relates to medical microbiology and is a strain of bifidobacteria, which can be used to prepare bacterial therapeutic and prophylactic bifidobacteria.
Препараты, содержащие в качестве действующего начала бифидобактерии, предназначены для нормализации микрофлоры кишечника людей, страдающих дисбактериозом, возникающим в результате перенесенных кишечных заболеваний, длительной антибиотикотерапии, лучевой и химиотерапии, стрессовых воздействий и т.п. Preparations containing bifidobacteria as an active principle are intended to normalize the intestinal microflora of people suffering from dysbiosis resulting from past intestinal diseases, prolonged antibiotic therapy, radiation and chemotherapy, stress exposure, etc.
Известны зарубежные препараты-эубиотики, содержащие в качестве действующего начала бифидобактерии (патент 2336886; патент 2411008, Франция; патент 637297, Швейцария; патент 2134179, патент 2421066, ФРГ). У нас в стране для приготовления бактерийных препаратов применяют отечественные штаммы бифидобактерий видов B.bifidum, B.longum (авт. св. N 343588, патент 1347221, патент 849779, патент 1692021, SU а.с. N 1513029, RU, патент N 2001101, кл. C 12 N 1/20, 1993)
Бифидофлора человека представлена пятью видами B.bifidum, B.longum, B. adolescentis, B.breve и B.infantis. Первые три вида встречаются в биоценозе кишечника с наибольшей частотой, в 39-75% случаях. Виды B.breve и B.iefaetis обнаруживаются реже, в 16-36% случаях и только у детей грудного возраста. Поскольку эти виды свойственны детям раннего возраста, то и использование одного из них, B.breve, при разработке препаратов-эубиотиков на его основе весьма перспективно.Foreign eubiotics are known containing bifidobacteria as an active principle (patent 2336886; patent 2411008, France; patent 637297, Switzerland; patent 2134179, patent 2421066, Germany). In our country, for the preparation of bacterial preparations, domestic strains of bifidobacteria of the species B. bifidum, B. longum are used (ed. St. N 343588, patent 1347221, patent 849779, patent 1692021, SU A.S. N 1513029, RU, patent N 2001101 Cl. C 12 N 1/20, 1993)
Human bifidoflora is represented by five species of B. bifidum, B. longum, B. adolescentis, B.breve and B.infantis. The first three species are found in the intestinal biocenosis with the greatest frequency, in 39-75% of cases. Species B.breve and B.iefaetis are found less frequently, in 16-36% of cases, and only in infants. Since these species are characteristic of young children, the use of one of them, B.breve, in the development of eubiotics based on it is very promising.
Нами предложен штамм Bifidobacterium breve подвид parvulorum 79-119, способный активно размножаться и наращивать микробную массу в короткие, 16-24 ч, сроки культивирования, и обладающий кислотопродуцирующим и антагонистическими свойствами. We proposed a strain of Bifidobacterium breve subspecies parvulorum 79-119, capable of actively multiplying and increasing microbial mass in short, 16-24 hours, cultivation periods, and possessing acid-producing and antagonistic properties.
Штамм Bifidobacterium breve 79-119 выделен из содержимого кишечника здорового грудного ребенка в 1979 г, хранится в лиофилизированном состоянии и депонирован под N 153 в Государственной коллекции микроорганизмов - представителей нормальной микрофлоры человека (ГКНМ) Московского НИИ эпидемиологии и микробиологии им Г.Н. Габричевского. The strain Bifidobacterium breve 79-119 was isolated from the intestines of a healthy infant in 1979, stored in a lyophilized state and deposited under No. 153 in the State collection of microorganisms - representatives of normal human microflora (GKNM) of the G.N. Gabrichevsky.
Культурально-морфологические признаки. Cultural and morphological characters.
Клети палочковидные, изящные, с Y-образными раздвоениями на одном или двух концах; неподвижные, склонные к образованию скоплений, грамположительные. В печеночной среде Блаурокка образует колонии в виде комет. Логарифмическая фаза роста заканчивается к 24 часам. В жидких питательных средах растет по всей высоте объема, кроме зоны аэробиоза. The cages are rod-shaped, graceful, with Y-shaped forks at one or two ends; motionless, prone to the formation of clusters, gram-positive. In the hepatic environment, Blaurocca forms colonies in the form of comets. The logarithmic growth phase ends by 24 hours. In liquid nutrient media it grows along the entire height of the volume, except for the aerobiosis zone.
Физиолого-биохимические признаки. Physiological and biochemical characteristics.
Неподвижный, бесспорный облигатный анаэроб. Оптимальная температура выращивания 37,5-38oC, pH питательных сред 7,2-7,4. Каталазу не образует, желатину не разжижает. Сбраживает глюкозу с образованием уксусной и L + молочной кислоты без образования газа, закисляя среду выращивания до pH 4,1-3,9. Ферментируют лактозу, маннозу, целлобиозу, вариабельно салицин, не утилизирует арабинозу, ксилозу, инуклин, маннит, сорбит. Сквашивает молоко к 16-24 часам с образованием плотного сгустка.Fixed, undisputed obligate anaerobic. The optimum temperature of cultivation is 37.5-38 o C, the pH of the nutrient medium is 7.2-7.4. Catalase does not form, gelatin does not dilute. It ferments glucose to form acetic and L + lactic acid without gas formation, acidifying the growth medium to a pH of 4.1-3.9. Ferment lactose, mannose, cellobiose, variable salicin, does not utilize arabinose, xylose, inuklin, mannitol, sorbitol. Fermented milk at 16-24 hours with the formation of a dense clot.
Штамм генетически маркирован. The strain is genetically tagged.
Штамм активно наращивает микробную массу на питательных средах культивирования, принятых в производстве бактерийных препаратов (табл.1). The strain is actively increasing the microbial mass in the culture media adopted in the production of bacterial preparations (table 1).
Штамм к 16-24 часам интенсивно размножается в питательных средах с высоким содержанием микробных клеток, что является одним из существенных показателей технологичности штамма. The strain at 16-24 hours intensively multiplies in nutrient media with a high content of microbial cells, which is one of the essential indicators of the technological strain.
Штамм обладает специфической активностью кислотообразующей и антагонистической. При культивировании на питательных средах продуцирует кислоты, более энергично- на гидролизатно-молочной (табл.2). The strain has specific acid-forming and antagonistic activity. When cultivated on nutrient media, it produces acids, more vigorously on hydrolyzate-lactic acid (Table 2).
Штамм подавляет рост патогенных и условно-патогенных микроорганизмов - Шигеля Зонне, Флекснера, энтеропатогенных кишечных палочек, стафилококка, протея (табл.3). Излучение спектра чувствительности к 15 применяемым антибактериальным препаратам выявило, что штамм устойчив к канамицину, неомицину, оксациллину, цефалотину, тетрациклину, линкомицину, стрептомицину; среднеустойчив к олеандомицину; чувствителен к ампициллину, бензилпенициллину, карбенициллину, эритромицину, левомицетину, ристомицину, рифампицину. The strain inhibits the growth of pathogenic and conditionally pathogenic microorganisms - Shigel Sonne, Flexner, enteropathogenic Escherichia coli, staphylococcus, Proteus (table 3). Radiation of the sensitivity spectrum to 15 antibacterial drugs used revealed that the strain is resistant to kanamycin, neomycin, oxacillin, cephalotin, tetracycline, lincomycin, streptomycin; medium resistant to oleandomycin; sensitive to ampicillin, benzylpenicillin, carbenicillin, erythromycin, chloramphenicol, ristomycin, rifampicin.
Из приведенных данных следует, что штамм 79-119 активно размножается на питательных средах, принятых в производстве бактерийных препаратов, с высоким содержанием микробных клеток в короткие, 16-24 ч, сроки культивирования; обладает высококислотопродуцирующими и ингибирующими свойствами в отношении патогенных и условно-патагенных микроорганизмов; обладает устойчивостью к ряду антибактериальных препаратов. From the above data it follows that strain 79-119 actively propagates on nutrient media adopted in the production of bacterial preparations with a high content of microbial cells in short, 16-24 hours, cultivation periods; possesses highly acid-producing and inhibitory properties against pathogenic and conditionally pathogenic microorganisms; It is resistant to a number of antibacterial drugs.
Пример. Штамм 79-119 1-2-3-го пассажей культивируют при 37,5-38oC и pH среды 7,2-7,4 в течение 16-24 ч. К выращенной биомассе добавляют защитные среды высушивания (сахароза 80% и желатина 8% 10-12% обезжиренное молоко до 20% ). Полученную суспензию разливают по 2 ил в ампулы или по 5 мл в пенициллиновые флаконы, замораживают при 40o-45oC и лиофилизируют из замороженного состояния в вакуум-сушильных аппаратах. Полученный препарат при выпуске содержит 108-109 живых клеток бифидобактерий.Example. Strain 79-119 of the 1-2-3rd passages was cultured at 37.5-38 ° C and a pH of 7.2-7.4 for 16-24 hours. Protective drying media (sucrose 80% and gelatin 8% 10-12% skim milk up to 20%). The resulting suspension is poured in 2 silt into ampoules or 5 ml in penicillin vials, frozen at 40 o -45 o C and lyophilized from a frozen state in vacuum dryers. The resulting preparation upon release contains 10 8 -10 9 live bifidobacteria cells.
Согласно НТД на сухой бифидумбактерин (ФС 42-132 ВС-94) содержание в 1 дозе препарата должна составлять не менее 107 бифидобактерий.According to the NTD for dry bifidumbacterin (FS 42-132 BC-94), the content in 1 dose of the drug should be at least 10 7 bifidobacteria.
Таким образом, предлагаемый штамм B.breve 79-119 является технологичным, поскольку энергично размножается в питательных средах с накоплением производственной биомассы в короткие сроки культивирования. Штамм можно рекомендовать для использования его в качестве основы при производстве бактерийных препаратов-эубиотиков. Thus, the proposed strain of B.breve 79-119 is technologically advanced, since it propagates vigorously in nutrient media with the accumulation of production biomass in a short period of cultivation. The strain can be recommended for use as a basis in the production of bacterial eubiotics.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU9595100750A RU2078815C1 (en) | 1995-01-17 | 1995-01-17 | Strain of bacterium bifidobacterium breve used for preparing the bacterial curative-prophylaxis bifido-containing preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU9595100750A RU2078815C1 (en) | 1995-01-17 | 1995-01-17 | Strain of bacterium bifidobacterium breve used for preparing the bacterial curative-prophylaxis bifido-containing preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU95100750A RU95100750A (en) | 1996-07-10 |
| RU2078815C1 true RU2078815C1 (en) | 1997-05-10 |
Family
ID=20164112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU9595100750A RU2078815C1 (en) | 1995-01-17 | 1995-01-17 | Strain of bacterium bifidobacterium breve used for preparing the bacterial curative-prophylaxis bifido-containing preparations |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2078815C1 (en) |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2176270C2 (en) * | 2000-01-24 | 2001-11-27 | Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского | Strain bifidobacterium breve 79-88 used for preparing curative-prophylactic fermented-milk, nonfermented-milk food-stuffs, biologically active supplements and bacterial preparations |
| RU2261905C1 (en) * | 2004-10-20 | 2005-10-10 | Общество с ограниченной ответственностью "Мир биотехнологий (НПО)" | BIFIDUS-BACTERIUM STRAIN Bifidobacterium breve USEFUL IN PREPARATION OF FERMENTED-MILK AND NONFERMENTED PRODUCTS, BIOACTIVE SUPPLEMENT, BIFIDOBACTERIA-CONTAINING PRODUCT, COSMETIC AND TOILETRY AGENTS |
| RU2373274C1 (en) * | 2008-07-15 | 2009-11-20 | Федеральное Государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Bifidobacterium breve ov-12 strain, used for making bacterial preparations, bioligically active additives to food, fermented and unfermented food products, hygienic and cosmetic agents |
| US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
| US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
| US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
| US12048720B2 (en) | 2017-06-14 | 2024-07-30 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
-
1995
- 1995-01-17 RU RU9595100750A patent/RU2078815C1/en active
Non-Patent Citations (1)
| Title |
|---|
| 1. Авторское свидетельство N 1513029 кл. C 12 N 1/20, 1989. 2. Патент РФ N 2001101, кл. С 12 N 1/20, 1993. 3. Инструкция по применению бифидум бактерина сухого, утв. 10.02.89. Минздрав РСФСР, Предприятие по производству бактерийных препаратов МНИИЭМ им. Г.Н.Габричевского. * |
Cited By (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2176270C2 (en) * | 2000-01-24 | 2001-11-27 | Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского | Strain bifidobacterium breve 79-88 used for preparing curative-prophylactic fermented-milk, nonfermented-milk food-stuffs, biologically active supplements and bacterial preparations |
| RU2261905C1 (en) * | 2004-10-20 | 2005-10-10 | Общество с ограниченной ответственностью "Мир биотехнологий (НПО)" | BIFIDUS-BACTERIUM STRAIN Bifidobacterium breve USEFUL IN PREPARATION OF FERMENTED-MILK AND NONFERMENTED PRODUCTS, BIOACTIVE SUPPLEMENT, BIFIDOBACTERIA-CONTAINING PRODUCT, COSMETIC AND TOILETRY AGENTS |
| RU2373274C1 (en) * | 2008-07-15 | 2009-11-20 | Федеральное Государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Bifidobacterium breve ov-12 strain, used for making bacterial preparations, bioligically active additives to food, fermented and unfermented food products, hygienic and cosmetic agents |
| US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
| US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
| US11414463B2 (en) | 2013-04-10 | 2022-08-16 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10973872B2 (en) | 2014-12-23 | 2021-04-13 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
| US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10864236B2 (en) | 2015-06-15 | 2020-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11273185B2 (en) | 2015-06-15 | 2022-03-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11331352B2 (en) | 2015-06-15 | 2022-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11040075B2 (en) | 2015-06-15 | 2021-06-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744167B2 (en) | 2015-06-15 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11389493B2 (en) | 2015-06-15 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10780134B2 (en) | 2015-06-15 | 2020-09-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11433106B2 (en) | 2015-06-15 | 2022-09-06 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11058732B2 (en) | 2015-11-20 | 2021-07-13 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10960031B2 (en) | 2016-07-13 | 2021-03-30 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10967010B2 (en) | 2016-07-13 | 2021-04-06 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
| US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10543238B2 (en) | 2016-12-12 | 2020-01-28 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10898526B2 (en) | 2016-12-12 | 2021-01-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11376284B2 (en) | 2017-05-22 | 2022-07-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11382936B2 (en) | 2017-05-22 | 2022-07-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US12048720B2 (en) | 2017-06-14 | 2024-07-30 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
Also Published As
| Publication number | Publication date |
|---|---|
| RU95100750A (en) | 1996-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2078815C1 (en) | Strain of bacterium bifidobacterium breve used for preparing the bacterial curative-prophylaxis bifido-containing preparations | |
| EP0555618B1 (en) | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria | |
| RU2109054C1 (en) | Consortium of bifidobacterium bifidum 791, b longum b379m, b breve 79-119, b infantis 73-15, b adolescentis g7513 for preparing lactic acid nonfermented foodstuffs and bacterial preparations | |
| KR102269962B1 (en) | Eubacterium limosum strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof | |
| RU2120991C1 (en) | Strain of bifidobacterium adolescentis g-7513 used for preparing bifido-containing eubiotic preparations and products for curative-dietetic nutrition | |
| RU2152993C1 (en) | Strain of bifidobacterium bifidum vkpm ac-1578 used for preparing bacterial preparation and foodstuff product | |
| RU2375444C1 (en) | Bifidobacterium bifidum OV-19 STRAIN USED TO PREPARE BACTERIAL PREPARATIONS, BIOLOGICALLY ACTIVE FOOD ADDITIVES, FERMENTED AND UNFERMENTED FOODSTUFF, HYGIENIC AND COSMETIC PRODUCTS | |
| RU2048517C1 (en) | Strain of bacterium bifidobacterium longum used for preparing bacterial preparations and sourly milk products | |
| RU2268931C1 (en) | STRAIN Bifidobacterium bifidum 79-37 USED FOR PREPARING FERMENTED-MILK, FERMENTED AND NONFERMENTED FOODSTUFFS, FERMENTS, HYGIENIC AND COSMETIC AGENTS, BIOLOGICALLY ACTIVE SUPPLEMENTS AND BACTERIAL PREPARATIONS | |
| RU2373274C1 (en) | Bifidobacterium breve ov-12 strain, used for making bacterial preparations, bioligically active additives to food, fermented and unfermented food products, hygienic and cosmetic agents | |
| CN116445331B (en) | Pediococcus acidilactici ZJUIDS17 with high-yield gamma-aminobutyric acid effect and application thereof | |
| KR100609779B1 (en) | Lactic acid bacteria that break down alcohol and acetaldehyde | |
| KR102351145B1 (en) | Bifidobacterium longum strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof | |
| KR102296287B1 (en) | Lactobacillus fermentum strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof | |
| KR102269963B1 (en) | Coprococcus comes strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof | |
| RU2210592C1 (en) | Strain of bacterium bifidobacterium longum 58b for preparing biologically active supplements regulating intestine microflora in children of early age | |
| RU2078814C1 (en) | Strain of bacterium bifidobacterium breve used for curative-dietetic foodstuffs preparing | |
| RU2112034C1 (en) | Strain bifidobacterium infantis 73-15 used for preparing bifidum-containing bacterial preparations and products of curative-dietetic nutrition | |
| KR102331486B1 (en) | Bifidobacterium pseudocatenulatum strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof | |
| RU2111248C1 (en) | Strain of bifidobacterium infantis 79-43 used for addition to composition of bifidum-containing preparations-eubiotics and foodstuffs for curative-dietetic nutrition | |
| KR102296289B1 (en) | Lactobacillus gasseri strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof | |
| RU2215027C2 (en) | Strain of bacterium lactobacillus rhamnosus 12l for preparing biologically active supplement regulating intestine microflora in children of early age | |
| KR100299306B1 (en) | Lactic acid bacteria with high acid resistance and growth rate and excellent blood cholesterol lowering ability | |
| RU2061040C1 (en) | Strain of bacterium lactobacillus plantarum showing capability to decrease oxalate level and used for preparing preparations and foodstuffs for hyperoxaluria prophylaxis and treatment | |
| KR0142615B1 (en) | New Lactic Acid Bacteria with Excellent Acid Resistance and Cholesterol Degradation Isolated from Feces of Korean Infant and Their Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Invention patent assignment |
Effective date: 20080716 |